The difference is that MNTA got approval and all ITMN got was a relatively positive AC vote. I'm really surprised MNTA hasn't solidly doubled today. I think because their product is a generic drug it doesn't have the sexiness of other drugs. But M-Enox, as everyone here knows is not your typical generic drug with many competitors. There will be no disputing the numbers if M-Enox is sole generic for the foreseeable future along with Copaxone probably becoming a sole generic. Eventually someone will gobble MNTA up for a significant premium.
Market Data 
Markets 
AI
